Oruka Therapeutics (ORKA) Director Samarth Kulkarni Receives Award

What Happened

• Samarth Kulkarni, a director of Oruka Therapeutics, was granted an award covering 9,136 derivative shares (reported as an acquisition, code A) on 2026-06-02. The Form 4 lists the per-share amount as $0.00 and the transaction value as $0. This is an award/grant (compensation-related), not a sale or open-market purchase.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-03.
• Transaction type: Grant/Award of derivative securities (Form 4 code A).
• Quantity: 9,136 underlying shares; consideration reported: $0.00 (total $0).
• Vesting: Footnote states the option vests as to 1/12 of the underlying shares monthly beginning June 2, 2026.
• Shares owned after transaction: Not provided in the supplied data — see the full Form 4 for current beneficial ownership.
• Timeliness: Filing was submitted the day after the transaction date (appears within the normal Form 4 reporting window).
• Footnote: F1 — monthly vesting schedule (1/12 per month starting 6/2/2026).

Context

• This filing reports a compensation-related equity award (derivative securities) that will vest over time. It is not an immediate cash purchase or sale of shares. Awards like this typically reflect company compensation arrangements; they do not by themselves indicate immediate buying or selling in the market.
• The Form 4 lists $0.00 consideration for the grant, which means no cash was reported as paid for the acquisition on the filing — consult the company’s disclosure (e.g., proxy, press release) for precise award type (RSUs, stock options, etc.) and any exercise price or tax-withholding details.